See how your reported results read as versioned evidence records β linked to experiments and limitations.Know what the science actually supports before you trust the answer.
Press Enter β΅ to review claims
Explore by Goal
"The important thing is not to stop questioning. Curiosity has its own reason for existing."
The provided publication set spans marine ecology / ocean acidification and cancer immunology / T-cell immunotherapy. Citation impact signals breadth, but several key uncertainties remain: the review you provided includes only a small subset of works (and at least one dataset-like entry unrelated to the listed author papers), and we lack full-text methods/results for the specific papers you named, so effect-size quality and reproducibility canβt be audited here.
Long Explanation
Author Review: Daisuke Muraoka
Evidence policy: I only treat statements about paper content as grounded when a DOI is available from your input; I keep βauthor metricsβ as your provided OpenAlex values (not externally verified here).
1) What we can know from your input (known vs. uncertain)
Known from your input (not independently audited here): OpenAlex-style metrics (e.g., works_count, cited_by_count, h-index) and a small list of specific paper titles/DOIs/years you provided.
Uncertain / cannot audit from your input: Experimental design rigor, sample sizes, statistical power, blinding, preregistration, and reproducibility for the specific named papersβbecause your prompt does not include full-text methods/results for each cited-item.
Potential mismatch risk: Your author-paper list (4 marine/seaweed/ocean acidification papers) appears different from the OpenAlex βtop_worksβ you supplied (nanogel immunology / T-cell immunotherapy topics). I flag this because mixing domains is plausible for multi-field researchers, but it also increases the chance that the provided examples are not the same βsubset of outputsβ you intend to evaluate.
2) Citation-impact timeline (from your OpenAlex counts_by_year)
These plots reflect your provided OpenAlex βtop matchβ entry: works_count and cited_by_count by year.
3) Evidence-based thematic coverage (two domains) using your provided DOI-linked examples
Below I only analyze paper content claims when the DOI-linked record in your input provides a DOI and a short abstract-like excerpt.
Marine / ocean acidification (from your 4 listed papers; no DOIs provided in your input)
Your prompt lists these titles (but without DOIs): βCoverage-biomass relationships for seaweeds and surfgrass in Japanβ, βTransgenerational acclimation to acidified seawater and gene expression patterns in a sea urchin.β, βShort-term variation in pH in seawaters around coastal areas of Japan: characteristics and forcingsβ, and βEffects of ocean acidification on growth and spinous skeletal composition of the sea urchin β¦β.
Because DOIs werenβt provided for these marine papers in your input, I canβt quote or fact-check their key methodological details under the strict citation policy requested.
Cancer immunology / T-cell immunotherapy (DOI-linked records from your OpenAlex βtop_worksβ snippet)
Claim you provided via abstract excerpt: nanoparticulate cancer vaccine encapsulating a synthetic long peptide antigen, aiming at immunologically stealth targeting and antitumor immunity.
What matters scientifically: vaccine efficacy claims are highly sensitive to model system, antigen presentation context, dosing schedule, and whether functional readouts include T-cell specificity controls.
Antigen delivery to tumor-associated macrophages overcomes immune resistance (JCI, 2019)
Claim you provided via abstract excerpt: mechanisms of tumor immune resistance limit checkpoint inhibitors / T-cell therapies; antigen delivery targeting TAMs can overcome resistance.
Rigor check needed (not available here): whether improvements are causally linked to macrophage targeting (e.g., depletion/blockade controls), and whether off-target immune shifts confound βresistance overcameβ language.
Claim you provided via abstract excerpt: IL-17 is pleiotropic; implicated in inflammation/autoimmune disease; the study (per snippet) focuses on a distinct macrophage subpopulation regulating intestinal inflammation.
Blindspot to consider: macrophage phenotypes can be definition-sensitive (marker panels, single-cell vs bulk, functional polarization assays), so βM2-likeβ should be validated across assays.
Claim you provided via abstract excerpt: synthetic peptide CTL epitope vaccination has not been generally effective; study addresses mechanisms of failure (mechanistic emphasis).
Why this matters: mechanism-first work can reduce interpretive inflation compared with purely correlational βenhancementβ claimsβassuming adequate controls.
4) Scientific strength: what looks strong vs. what we canβt verify here
Strength signals (from your provided records/metrics)
Cross-domain output (marine + immunology): indicates the ability to operate in distinct biological measurement regimes (field/biogeochemistry vs. immunology assays), which is often correlated with adaptability.
Impact breadth (OpenAlex top match you provided): works_count = 89 and cited_by_count = 1308 with h_index = 17 (per your provided OpenAlex βtop_authorβ record).
Mechanism-aware immunology examples: at least one DOI-linked record you included explicitly frames βfailure mechanismsβ rather than solely reporting positive outcomes ().
Main uncertainties / skeptical flags
Selection bias from the subset shown: your prompt mixes (a) 4 marine titles without DOIs and (b) an OpenAlex βtop_worksβ list with DOI-linked immunology examples. Without the full publication list + DOIs for the marine works, domain-level claims about βwhat the author really does bestβ canβt be robust.
Reproducibility audit gap: we donβt have methods, raw numbers, variance, or statistical details for the DOI-linked examples beyond snippets. Citation count is not proof of methodological quality.
Labeling bias risk: phrases like βstealth,β βpotent antitumor immunity,β βovercomes resistance,β and βM2-likeβ are interpretive. True scientific strength requires assay-specific evidence and causal controls (not provided here).
Dataset/annotation biases: if any of these works rely on curated immunology annotations or target identification, public-domain biases can propagateβthis is a general risk; we canβt quantify it here.
5) Suggested BGPT follow-ups (actionable)
Confidence statement
Confidence in authorβs broad activity and citation impact: moderate (because your OpenAlex metrics are taken as given).
Confidence in specific scientific rigor and causal claims across the mentioned papers: low-to-moderate (because we lack full-text methods/results and only have abstract-like snippets for a few DOI-linked examples).
What would disprove/change my assessment: if full-text reviews reveal major methodological weaknesses in the DOI-linked immunology papers (e.g., insufficient controls for targeting claims, weak/absent blinding/randomization, or non-replicated key findings), or if the marine works dominate the authorβs measured contributions and the immunology examples are a different researcher with name ambiguity.
Feedback:
Updated: April 01, 2026
BGPT Author Review
Scientific Quality
60%
Moderate-to-good scientific quality signals from your provided citation-impact metrics and from DOI-linked immunology examples that include mechanistic framing (not only phenomenology). However, the evaluation is underdetermined because the marine set lacks DOIs/full-text details, and the immunology paper content is based on snippets onlyβso key rigor elements (controls, statistics, replication, causal targeting evidence) canβt be audited. Overall: promising breadth, but insufficient evidence here to rate as high-rigor/field-leading with high confidence.
Communication Quality
60%
The prompt itself doesnβt include the authorβs writing style, figures, or conclusions. Communication quality is therefore inferred only indirectly from the prominence and standard journal context of provided examples, which is weak evidence. Net: moderate uncertainty; likely competent, but not verifiable from the provided material.
Author Novelty
50%
Novelty canβt be assessed rigorously without reading methods/discussion and comparing to prior baselines. The immunology examples suggest innovation in delivery/targeting and mechanistic framing, but novelty is not demonstrated here with comparative benchmarks or ablation details.
Scientific Rigor
50%
Rigor cannot be verified because the prompt lacks full-text methodological and statistical details for the specified papers. Snippet-level abstracts are insufficient to evaluate design strength, blinding/randomization, sample-size adequacy, or reproducibility.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
The hypothesis that βM2-likeβ macrophage markers alone fully determine IL-17-driven inflammation control is likely wrong because macrophage phenotypes are marker- and assay-definition dependent; functional causality must be shown, not assumed.
The hypothesis that βtargeting lymph-node medullary macrophagesβ guarantees therapeutic antitumor immunity in all tumor contexts is unlikely; the microenvironment and antigen presentation context typically modulate whether delivery translates into functional T-cell efficacy.
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Hypothesis Graveyard
Discussion